Late recurrence 5 or more years after diagnosis accounts for at least one-half of all cases of recurrent hormone receptor-positive breast cancer.
B reast cancer is the most common cancer and the leading cause of death from cancer among women, accounting for 25% of all cancers and 15% of deaths from cancer worldwide. 1, 2 Although most patients with breast cancer present with localized disease that is potentially curable with surgery and radiation, 3 recurrence in distant organs is common and incurable. 4 Adjuvant systemic therapies reduce distant recurrence and breast cancer mortality. 5 Adjuvant chemotherapy reduces recurrence primarily within 5 years after diagnosis, 6 whereas endocrine therapy reduces recurrence during a typical 5-year treatment course and after completion of endocrine therapy because of a carry-over effect. 7, 8 Recurrence 5 years or more after a diagnosis is commonly referred to as late recurrence and accounts for approximately one-half of all recurrences of hormone receptor-positive breast cancer, whereas recurrence 5 years or more after diagnosis is considerably less common among patients with hormone receptornegative disease. 9,10 Continuing tamoxifen therapy beyond 5 years or switching to an aromatase inhibitor are associated with reductions in recurrence and breast cancer mortality, [11] [12] [13] [14] whereas continuing therapy with aromatase inhibitors beyond 5 years is associated with marginal effects in reducing distant recurrence risk.
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Biomarkers prognostic for late recurrence potentially provide more accurate stratification of recurrence risk than clinicopathologic features. Although some multiparameter gene expression assays of the primary tumor can be used to determine both early and later recurrence [18] [19] [20] [21] [22] [23] and the efficacy of extended adjuvant endocrine therapy beyond 5 years, 24 the use of such assays is not recommended for guiding therapy beyond 5 years after diagnosis because they are associated with a modest degree of risk stratification and there is limited evidence of their clinical utility. 25, 26 Biomarkers that more robustly stratify risk are needed. Assays that use blood-based biomarkers such as circulating tumor cells (CTCs) 27 or circulating tumor DNA 28 (so-called liquid biopsies) have potential to address this unmet need but have not been evaluated for use in determining late recurrence in breast cancer. We describe here, to our knowledge for the first time, the prospective evaluation of a CTC assay used to determine late clinical recurrence of breast cancer 5 years after potentially curative local therapy and systemic adjuvant therapy.
Methods

Eligibility Criteria
The study population included patients enrolled in a completed E5103 adjuvant clinical trial ( 
CTC Assay
Whole blood samples were obtained in fixative-containing tubes (CellSave; Menarini Silicon Biosystems Inc) and sent to a central laboratory (Alpaugh Laboratory, Fox Chase Cancer Center, Philadelphia, PA) for CTC identification and enumeration using the CellSearch system, as described elsewhere.
31,32
The assay is a clinically validated, US Food and Drug Administration-cleared blood test for enumerating CTCs in patients with metastatic breast cancer. 31 Results were not reported to the treating clinician or patient because of the uncertainty regarding the prognostic information provided by the assay in this context.
Statistical Evaluation
Data analysis was performed in April 2018. An interim analysis was planned after accrual of approximately 233 patients, with further accrual to be halted if the CTC positivity rate was less than 1%, providing 90% power with a 1-sided type I error rate of 5% to distinguish between a true CTC positivity rate of 5% vs 10%. Accrual continued after the interim analysis when it was determined that the CTC positivity rate exceeded 1% and was discontinued after 3.4 years of accrual (and 5.4 years after enrollment of the last patient in the parent E5103 trial) because of slowing accrual. The primary analysis population included patients with an evaluable blood sample and no documented invasive recurrence within 30 days after or at any
Key Points
Question Are circulating tumor cells associated with late recurrence of breast cancer?
Findings In this secondary analysis of a randomized clinical trial, circulating tumor cells were detectable in 26 of 547 patients (4.8%) with localized breast cancer 5 or more years after diagnosis and were associated with a higher risk of recurrence among patients with hormone receptor-positive breast cancer.
Meaning Circulating tumor cells may be used to stratify for risk of late recurrence among patients with hormone receptor-positive breast cancer.
time before the CTC blood sample obtainment. The primary end point was time to recurrence, defined as the date of the CTC blood sample obtainment to the date of the first invasive distant, local, or regional recurrence; patients without documentation of invasive recurrence were censored at the date on which they were last known to be disease free. The Fisher exact test was used to compare groups with respect to patient characteristics. Clinical recurrences were determined by the local treating physician on the basis of clinical, radiographic, and pathologic information and were confirmed by a research coordinator in the Eastern Cooperative Oncology GroupAmerican College of Radiology Imaging Network (ECOG-ACRIN) data management center and the study principal investigator (K.D.M.). The Kaplan-Meier method was used to estimate time-to-recurrence distributions, and the log-rank test was used for comparison. Cox proportional hazards regression models were used to estimate hazard ratios. Recurrence rates were calculated as number of time-to-recurrence events divided by person-years of follow-up. P < .05 was considered to be statistically significant. P values were 2-sided. A positive CTC assay result was defined as at least 1 CTC per 7.5 mL of blood, and a negative CTC assay result was defined as no CTC detected in 7.5 mL of blood.
Results
Study Population
Of the 4994 patients enrolled in the parent E5103 trial, a total of 547 patients (9.1%) (mean [SD] age, 51.9 [9.4] years) without clinical evidence of recurrence and with an evaluable CTC assay result were included in the late recurrence substudy analysis between February 25, 2013, and July 29, 2016 ( Figure 1 ). There were no significant differences in the demographic and clinical characteristics of the substudy population and the population enrolled in the E5103 parent trial (eTable 1 in the Supplement). Twenty-six of 547 patients (4.8% [95% CI, 3.1%-6.9%]) had positive CTC assay results, with no significant differences noted in the characteristics of the CTC-positive and CTC-negative patients (eTable 2 in the Supplement). Of the 26 patients with a positive CTC assay result, 12 (46%) were 50 years or older at the time of diagnosis and registration for the E5103 parent study, 16 (62%) had a primary tumor size larger than 2 cm in diameter, 21 (81%) had at least 1 positive axillary node metastasis, 18 (69%) had hormone receptor-positive disease, and 12 (46%) had high-grade histologic findings. There were no significant differences in characteristics between the CTC-positive and CTC-negative groups. There were also no significant differences in the demographic and clinical characteristics of the late relapse substudy population and the patients enrolled in the parent trial who did not enroll in the substudy (eTable 2 in the Supplement).
Recurrence in the Study Population
At the time of the analysis, the median follow-up after the CTC assay was performed was 2.6 years (range, 1.6-4.4 years), and 24 of 547 patients had experienced clinical recurrence (4.4% [95% CI, 2.8%-6.5%), including 23 patients whose primary tumor was hormone receptor-positive at the original diagnosis and 1 patient with a hormone receptor-negative tumor at the original diagnosis. Twenty-two of 24 patients had recurrences that were in distant sites (including 2 patients with concurrent local regional recurrence), and 2 patients had recurrences that were in a local or regional site without distant recurrence (including the only patient in this study with hormone receptor-negative disease who experienced relapse). Recurrence occurred in 23 of 353 patients (6.5% [95% CI, 4.2%-9.6%]) with hormone receptor-positive disease, but it occurred in only 1 of 193 patients (0.5% [95% CI, 0%-2.9%]) with hormone receptor-negative disease. In the entire population, a positive CTC assay result was associated were receiving endocrine therapy. Among 23 patients with hormone receptor-positive disease who had a clinical recurrence, 18 were receiving endocrine therapy after study registration at the time that the CTC assay was performed (including 5 of 7 CTCpositive patients and 13 of 16 CTC-negative patients), and 5 of 7 patients with a positive CTC assay result and clinical recurrence experienced relapse while receiving endocrine therapy.
CTC Burden and Recurrence in the Hormone Receptor-Positive Population
The association between CTC burden and recurrence in 18 patients with hormone receptor-positive disease and a positive CTC assay result is depicted in eFigure 1 in the Supplement. The median CTC count was 1 per 7.5 mL of blood (range, 1-15 per 7.5 mL blood) among all 18 patients, 9 per 7.5 mL blood (range, 1-15 per 7.5 mL blood) among the 7 patients with recurrence, and 1 per 7.5 mL blood (range, 1-14 per 7.5 mL blood) among the 11 patients without recurrence. Recurrence occurred in 16 of 335 patients (4.8% [95% CI, 2.8%-4.8%]) with a CTC count of 0 cells per 7.5 mL blood, 2 of 12 patients (16.7% [95% CI, 2.1%-48.4%]) with a CTC count of 1 per 7.5 mL blood, and 5 of 6 patients (83.3% [95% CI, 35.9%-99.6%]) with a CTC count of 2 or more per 7.5 mL blood, which suggests that a numerically higher recurrence risk is associated with higher CTC burden.
CTC Burden in the Hormone Receptor-Negative Population
None of 8 patients with hormone receptor-negative disease and a positive CTC assay result had a recurrence (0% [95% CI, 0%-37.0%]). Seven patients had a CTC count of 1 per 7.5 mL blood, and 1 patient had 2 per 7.5 mL blood. The median follow-up time after a positive CTC assay result was 2.8 years (range, 0-2.9 years).
Discussion
Late recurrence accounts for at least one-half of all cases of recurrence among patients with localized hormone receptorpositive breast cancer. Among 62 923 patients with hormone receptor-positive breast cancer who completed 5 years of endocrine therapy evaluated in the Early Breast Cancer Collaborative Trialists Group database, the ensuing 5-year risk of distant recurrence for patients with 0, 1 to 3, and 4 to 9 positive axillary nodes was approximately 6%, 10%, and 22%, respectively. 33 We prospectively evaluated, for the first time to our knowledge, the association between the presence of CTCs determined using an analytically validated bloodbased assay at 5 or more years after diagnosis and late clinical recurrence of operable breast cancer. All patients received primary surgical therapy and participated in a prospective clinical trial that included adjuvant systemic chemotherapy and Earlier studies have evaluated the prognostic information provided by the same CTC assay for breast cancer at diagnosis. Lucci et al 36 detected CTCs in 24% of 302 patients with stage I-III breast cancer at the time of primary surgery; after a median follow-up of 2.9 years, a positive CTC assay result was associated with a 4.6-fold increased risk of recurrence. Likewise, among 2026 patients with stage I-III breast cancer, Rack et al 37 reported a 2.1-fold higher risk of recurrence after a median follow-up of 2.9 years among the 22% of patients who had a positive CTC assay result before or after adjuvant chemotherapy. A pooled analysis of individual data from 3173 patients with stage I-III breast cancer, including the 2 earlier reports, likewise showed that CTCs were detected in 20.2%, and the presence of CTCs was an independent prognostic factor in multivariate analysis for distant recurrence and breast cancer mortality. 38 However, the CTC assay is currently not recommended to guide adjuvant therapy, 26 largely because of the modest degree of risk stratification and lack of effect on clinical management associated with the assay. Other blood-based biomarkers, such as circulating MUC-1 antigen assays (eg, CA15-3 and CA 27.29), have been evaluated for active surveillance with the goal of early detection of recurrent breast cancer, although not specifically for late recurrence. Sensitivity ranged from approximately 40% to 60%, the lead time between a positive assay result and clinical recurrence ranged from 3 to 6 months, and survival was not improved for those who underwent active surveillance.
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Despite the limitations associated with these assays and the diagnostic imaging and therapeutic interventions available at the time, evidence from other randomized trials suggests that early intervention based on active surveillance using circulating MUC-1 antigen assays may delay clinical evidence of recurrence. 43 
Limitations
There are several limitations of this study. The sample size was small, resulting in wide confidence intervals for the various point estimates examined. The median follow-up time of 2.6 years is relatively short for hormone receptor-positive breast cancer, and more recurrences among the CTC-negative group with longer follow-up could result in a lower degree of risk stratification. Most patients were receiving endocrine therapy before the blood samples were obtained for the CTC assay, and the study was not designed to determine whether a negative CTC assay result could identify patients who could be effectively spared continued endocrine therapy because of a low risk of late recurrence. The study also excluded patients with human epidermal growth factor receptor 2-overexpressing disease, who are also at risk for late recurrence if they are hormone receptor positive. 55 The CTC assay was performed at only a single time point between approximately 4.5 and 7.5 years after diagnosis, resulting in knowledge gaps about serial use of the assay or use before or after those time points for active surveillance. The CTC assay was not evaluated in the context of other assays, including commercial tumor antigen assays or emerging technologies, such as tests to determine circulating tumor DNA. 56 The CTC assay results were unknown to the clinician and patient and did not trigger imaging studies if they were positive, which could impact the sensitivity and specificity of assay results and the lead time between a positive assay result and cancer recurrence. 
